Clinical Features and Outcomes of Idiopathic Pulmonary Alveolar Proteinosis in Korean Population by Byun, Min Kwang et al.
INTRODUCTION
Pulmonary alveolar proteinosis (PAP) was first described
by Rosen et al. in 1958 (1). It is a rare disorder in which lipo-
proteinaceous material accumulates within alveoli. The clin-
ical course of the disease is variable, ranging from spontaneous
resolution to death due to pneumonia or respiratory failure.
Pulmonary alveolar proteinosis occurs in three clinically dis-
tinct forms: congenital, secondary, and idiopathic (acquired).
Congenital PAP is a heterogeneous group of disorders (2)
caused by mutations in the genes encoding surfactant pro-
tein B, C or bc chain of the receptor for granulocyte-macro-
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Clinical Features and Outcomes of Idiopathic Pulmonary Alveolar 
Proteinosis in Korean Population
Idiopathic pulmonary alveolar proteinosis (PAP) is a rare disorder in which lipopro-
teinaceous material accumulates within alveoli. There were few reports on Asian
populations with idiopathic PAP. We retrospectively reviewed 38 patients with idio-
pathic PAP in Korea. We assessed clinical features, therapeutic efficacy and out-
comes of whole lung lavage in patients with idiopathic PAP. The mean age at diag-
nosis was 52 yr. Eighty six percent of patients were symptomatic at diagnosis. Dys-
pnea and cough were the most common symptoms. Crackles were the most com-
mon physical examination finding. On pulmonary function test, a mild restrictive ven-
tilatory defect was common, with a predicted mean forced vital capacity (FVC) of
77% and forced expiratory volume in one second (FEV1) of 84.6%. Diffusing capaci-
ty was disproportionately reduced at 67.7%. Arterial blood gas analysis revealed
hypoxemia with a decreased PaO2 of 69.0 mmHg and an increased D(A-a)O2 of
34.2 mmHg. After whole lung lavage, PaO2, D(A-a)O2 and DLCO were significantly
improved, but FVC and total lung capacity (TLC) were not different. This is the first
multicenter study to analyze 38 Korean patients with idiopathic PAP. The clinical
features and pulmonary parameters of Korean patients with idiopathic PAP are con-
sistent with reports in other published studies. Whole lung lavage appears to be the
most effective form of treatment.
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phage colony stimulating factor (GM-CSF) (3, 4). Secondary
PAP occurs as a consequence of any one of a heterogeneous
group of underlying clinical conditions (hematologic cancers,
pharmacologic immunosuppression, inhalation of inorganic
dust or toxic fumes, and certain infections) that impair alve-
olar macrophage function, resulting in surfactant accumula-
tion (5). Idiopathic (acquired) PAP is a disorder of unknown
etiology that is thought to represent approximately 90% of
PAP cases. The prevalence of idiopathic pulmonary alveolar
proteinosis has been estimated to be 0.37 per 100,000 per-
sons (6-9). The median age at the time of diagnosis is 39 yr;
most patients are men, and 72% have a history of smoking
(10). Idiopathic pulmonary alveolar proteinosis is an enigmat-
ic and fascinating disorder (1). Recent observations in trans-
genic mice and humans, however, have provided important
clues about its pathogenesis. The first real clue was provid-
ed by the discovery that mice deficient in GM-CSF develop
a lung phenotype that is biochemically, histologically, phys-
iologically, and ultrastructurally indistinguishable from idio-
pathic PAP (11, 12).
The observation of PAP in GM-CSF-deficient mice was
quickly followed by the evaluation of GM-CSF therapy, first
in a single patient and then in several small series of patients
(13-16). GM-CSF deficiency has not been reported in humans
(17, 18). However, a second vital pathogenic clue was the
observation that primary PAP is specifically and strongly
associated with very high levels of GM-CSF autoantibodies
(19).
So far, most reports have focused on PAP patients from
western countries, but reports on Asian populations are ext-
remely rare, with only one report based on a Japanese popu-
lation (20). The first case in Korea was reported in 1987 (21)
and Kim and colleagues reviewed twelve cases in 1999 (22).
We reviewed the clinical features, treatment outcomes, and
prognosis of patients with idiopathic PAP in Korea.
MATERIALS AND METHODS
We retrospectively reviewed patients with idiopathic PAP
that were diagnosed between 1993 and 2007. The data were
collected from 10 clinical research centers in Korea (College
of Medicine in University of Ulsan, Seoul National Univer-
sity, Yonsei University, Sungkyunkwan University, Korea
University, Kyungpook National University, Soonchunhyang
University, Gachon University, Hallym University, and Inha
University). Patients with PAP were identified by review of
the Korean Interstitial Lung Disease Study Group. The medi-
cal records of eligible patients were reviewed by one investi-
gator of each institution, and data were extracted using a stan-
dard data collection instrument. The diagnosis of PAP was
confirmed by a physician diagnosis and pathologic specimens
were obtained by video-assisted thoracoscopic surgery or trans-
bronchial lung biopsy with bronchoalveolar lavage (BAL).
The symptoms and signs present at the initial assessment at
each institution were used as data. We contacted patients by
telephone to ascertain follow-up information and outcomes.
Arterial blood gas analysis, spirometry, and lung volume mea-
surements were estimated at diagnosis and if possible, esti-
mated again after whole lung lavage. We assessed the effica-
cy of whole lung lavage based on these parameters. 
RESULTS
We identified 38 patients (24 males and 14 females) with
PAP. The mean age at diagnosis was 52 yr (Table 1). There
were no cases of PAP due to occupational exposure. 
Eighty six percent of patients were symptomatic at diag-
nosis and the most common symptom at presentation was
dyspnea, and followed by cough (Table 2). The most promi-
nent finding on physical examination was crackles in 50%
of patients, with cyanosis present in one patient. The chest
radiographs for all but one patient showed bilateral air-space
Parameters No. Mean±SD Range
Age (yr) 38 51.6±12.8 15-81
Male (%) 24 63.2%
WBC (×10
3/mL) 37 6.7±2.2 3.5-13.9
Hb (g/dL) 37 14.2±2.3 8.8-19.7
LDH (IU/L) 21 455±183 153-834
CEA (ng/mL) 11 6.8±6.8 1.8-25.6
PaO2 (mmHg) 31 69.0±14.2 39.7-93.7
D(A-a)O2 (mmHg) 28 34.2±15.9 6.8-67.4
FEV1 (% pred) 32 84.6±20.8 30-119
FVC (% pred 32 77.3±17.7 45-107
TLC (% pred) 25 81.9±16.0 46-110
DLCO (% pred) 28 67.7±31.6 17-131
Table 1. Demographic and clinical features upon diagnosis of
idiopathic pulmonary alveolar proteinosis in Korean patients
Symptoms No. %
Dyspnea 25 50
Cough 12 24
Sputum 5 10
Fatigue 1 2
Chest pain 1 2
Epigastric pain 1 2
Asymptomatic 5 10
Table 2. Symptoms of Korean patients with idiopathic pulmonary
alveolar proteinosis at presentation
WBC, white blood cell; Hb, hemoglobin; LDH, lactate dehydrogenase;
CEA, carcinoembryogenic antigen; PaO2, partial pressure of oxygen in
arterial blood; D(A-a)O2, alveolar-arterial O2 gradient; FEV1, forced expi-
ratory volume in one second; FVC, forced vital capacity; TLC, total lung
capacity; DLCO, diffusing capacity of the lung for carbon monoxide. *Some patients presented with more than one symptom.Pulmonary Alveolar Proteinosis in Korean Population 395
disease with an ill-defined nodular or confluent pattern. High
resolution computed tomography showed patchy ground-glass
opacifications with superimposed interlobular septal thick-
ening in all patients.
On pulmonary function testing, a mild restrictive ventila-
tory defect was common, the mean percent predicted forced
vital capacity (FVC) was slightly decreased at 77%, the mean
percent predicted forced expiratory volume in one second
(FEV1) was normal at 84.6%, but the mean percent predict-
ed total lung capacity (TLC) of 81% was not decreased. How-
ever, the percent predicted diffusing capacity of the lung for
carbon monoxide (DLCO) was disproportionately reduced (mean
±SD; 67.7±31.6) among 29 patients. Arterial blood gas
analysis showed hypoxemia with a mean room air partial pres-
sure of oxygen (PaO2) of 69.0±14.2 mmHg and a mean alve-
olar arterial O2gradient; D(A-a)O2 of 36.0±4.4 mmHg. The
serum lactate dehydrogenase (LDH) level was elevated with
a mean value of 455.4±183.1 IU/L (range 153 to 834 IU/
L). Transbronchial lung biopsy was performed in 35 patients
(92%) and video-assisted thoracoscopic surgery was perform-
ed in 16 patients (42%). Diagnosis was established by trans-
bronchial lung biopsy with BAL or surgical lung biopsy. On
light microscopic examination, we observed the characteristic
finding of alveoli filled with a granular, eosinophilic material
that stained with periodic acid-Schiff, and a well-preserved
alveolar architecture. Whole lung lavage was indicated for
patients who presented with dyspnea or hypoxemia and dete-
riorated chest radiography. Whole lung lavage was performed
in 26 patients (68%), of whom 11 patients underwent another
lavage. We defined the recurrence as significant progression
of respiratory symptoms attributable to PAP or the applica-
tion of further therapeutic interventions such as repeated lavage.
Five patients (13.2%) showed spontaneous resolution after
unspecified periods of observation. We analyzed oxygenation/
hypoxemia, spirometric measurements, lung volume param-
eters, and radiologic findings before and after whole lung lavage
(Table 3). Oxygenation improved dramatically after therapeu-
tic lavage, and hypoxemia was corrected in 16 of 17 patients
for whom data were available. D(A-a)O2 also improved after
lung lavage. Spirometric results before and after whole lung
lavage were available for 12 patients. FVC improved in eight
patients and worsened in four patients. There was no signif-
icant difference in the mean FVC before and after whole lung
lavage (P=0.388), as analyzed using the Wilcoxon signed rank
test. FEV1 was increased in six patients and decreased in six
patients. The difference in FEV1 before and after whole lung
lavage was not statistically significant (P=0.609). Eight of nine
patients showed improvement in lung volume measurements
following therapeutic lavage. DLCO after whole lung lavage
showed significant improvement (P=0.015). TLC showed a
slight improvement after lavage, but the difference before and
after lavage was not significant (P=0.089). Using radiologic
evaluation with chest radiography or chest computed tomog-
raphy, we found that 22 of 26 patients (85%) had improved
after whole lung lavage therapy. Radiologic studies after lavage
was unavailable in 2 patients, no changes in 2 patients. The
mean follow-up period was 3 yr (range, 0.04 to 11.5 yr). At
the end of the study, 20 patients were alive, 2 patients had
died, and 16 patients were no longer available for follow-up.
One patient died soon after the whole lung lavage and the
other patient died of advanced gastric cancer. The definition
of disease recurrence varied between reports, but significant
progression of respiratory symptoms due to PAP and the appli-
cation of further therapeutic lavage were considered as recur-
rences. PAP recurred in 4 out of 24 patients (16.7%) during
the follow-up period. Of the four patients with a recurrence
of PAP, three underwent another whole lung lavage and the
fourth patient was closely observed without lavage. 
DISCUSSION
PAP was first recognized in 1958 by Rosen and colleagues
(1). Since then, there have been several reports on the clini-
cal respects of idiopathic PAP. Seymour and Presneill (10) ana-
lyzed 410 identifiable separate cases of PAP in 241 separate
initial publications; most of these cases involved patients from
western countries. Asamoto and colleagues (20) reported on
the clinical manifestations of PAP in a Japanese population.
The Japanese report was unique because it focused on an Asian
population with idiopathic PAP, but it was different from
the retrospective meta-analysis by Seymour and colleagues
(10) in several respects. First, two-thirds of the pathologic
diagnoses were established by bronchoscopic biopsy instead
of surgical lung biopsy. Further, it reported that the therapeu-
tic outcomes of whole lung lavage were superior to those of
other studies (Table 4). Before our study, however, this was
the only data available on idiopathic PAP in Asian popula-
tion. In this study, we retrospectively reviewed 38 patients
with idiopathic PAP in Korea. All the Korean patients were
born and had grown up in Korea. The median age at diag-
Variables No. P value
� Post-lavage* Pre-lavage*
PaO2, mmHg 17 64.9±11.1 77.3±15.7 0.005
D(A-a)O2, mmHg 16 35.3±12.4 20.1±13.2 0.001
FEV1, % pred 12 75.1±22.1 76.3±17.9 0.609
FVC, % pred 12 66.3±17.3 68.2±11.9 0.367
TLC, % pred 7 73.6±9.5 80.6±13.2 0.089
DLCO, % pred 9 53.9±22.3 65.2±17.6 0.024
Table 3. Pre-lavage and post-lavage pulmonary parameters for
patients with idiopathic PAP
*Mean±SD (standard deviation); 
� P value is from the Wilcoxon signed
rank test for comparison of pre-lavage versus post-lavage data for each
parameter from each patient for whom data were available.
PaO2, partial pressure of oxygen in arterial blood; D(A-a)O2, alveolar-arte-
rial O2 gradient; FEV1, forced expiratory volume in one second; FVC,
forced vital capacity; TLC, total lung capacity; DLCO, diffusing capacity
of the lung for carbon monoxide.396 M.K. Byun, D.S. Kim, Y.W. Kim, et al.
nosis was 52 yr for both genders, which is in contrast to the
distribution of patients from the report by Seymour and Pres-
neill (10) who reported a median age of 39 yr and a different
median age in men and women (Table 4). The median age
in our study was close to that of the recent report on autoim-
mune PAP in Japan by Inoue and colleagues (23). 
Recently, the use of surgical lung biopsy has decreased (24,
25) because a diagnosis of PAP can be established in approx-
imately 75% of clinically suspected cases based on the typi-
cal findings of a milky fluid from the BAL (25) that contains
large and foamy alveolar macrophages or monocyte-like alve-
olar macrophage and an increased numbers of lymphocytes
(26, 27). There are relatively few inflammatory cells of other
cell types, unless superinfection is present. There is also a large
amount of amorphous, lipoproteinaceous material that is char-
acteristically eosinophilic, granular, and positive with a peri-
odic acid-Schiff stain (25, 27). In this study, pathologic diag-
nosis was established by surgical lung biopsy (42%) or trans-
bronchial biopsy with BAL (58%). Milky fluid on BAL and
consistent transbronchial lung biopsy specimens provided
diagnosis, such as surgical lung biopsy.
Pulmonary function test at diagnosis showed results that
were similar to those of previous studies: a restrictive defect,
with a disproportionate reduction in diffusing capacity, a slight-
ly decreased mean FVC of 77.3% and a moderately decreased
DLCO of 67.7%. Arterial blood gas analysis at the initial pre-
sentation also showed the same results; PaO2 was decreased
to 69.0 mmHg and D(A-a)O2 was increased to 35.3 mmHg
Fig. 1. Paired pre-lavage and post-lavage arterial blood gas analysis data from patients with idiopathic PAP. The P value is for the com-
parison of pre-lavage versus post-lavage data for individual patients for each parameter for only those patients with available data using a
Wilcoxon signed rank test. The number of evaluable patients for each parameter: PaO2 (n=17), D(A-a)O2 (n=16).
Fig. 2. Paired pre-lavage and post-lavage pulmonary function data from patients with idiopathic PAP. The P value is for the comparison of
pre-lavage versus post-lavage data for individual patients for each parameter for only those patients with available data using a Wilcoxon
signed rank test. The number of evaluable patients for each parameter: FEV1 (n=12), FVC (n=12), TLC (n=7), DLCO (n=9).
Pre Post
P=0.005 P=0.001
P
a
O
2
(
m
m
H
g
)
100
80
60
40
20
0
Pre Post
D
(
A
-
a
)
 
O
2
(
m
m
H
g
)
100
80
60
40
20
0
P=0.609
F
E
V
1
(
%
 
p
r
e
d
)
150
100
50
0
Pre Post
P=0.367
F
V
C
 
(
%
 
p
r
e
d
)
150
100
50
0
Pre Post
P=0.089
T
L
C
 
(
%
 
p
r
e
d
)
150
100
50
0
Pre Post
P=0.024
D
L
c
o
(
%
 
p
r
e
d
)
150
100
50
0
Pre Post
*Cases establishing diagnosis by autopsy, not shown.
NA=not available.
Diagnostic procedure (%)*
Surgical lung
biopsy
Autopsy
Broncho-
scopy
No.
Mean 
age (yr)
Whole lung
lavage 
(%)
Mortality
(%)
Male
(%)
Study
(Reference)
Rosen et al. (1958) (1) 27 34 78 0 78 19 NA 30
Prakash et al. (1987) (9) 34 41 71 12 76 6 62 9
Asamoto et al. (1995) (20) 68 44 75 90 10 0 82 0
Seymour and Presneill (2002) (10) 410 39 71 10 71 11 54 16
Current study  38 52 63 58 42 0 68 5
Table 4. Comparison of published pulmonary alveolar proteinosis studiesPulmonary Alveolar Proteinosis in Korean Population 397
at the initial presentation. The efficacy of whole lung lavage
was evaluated with radiologic findings and pulmonary func-
tion tests. After the therapeutic lavage, oxygenation param-
eters such as PaO2 and D(A-a)O2 improved significantly in
comparison to the initial examinations (Fig. 1). DLCO also
increased dramatically. FVC and TLC improved slightly, but
this improvement was not statistically significant (Fig. 2).
These results are similar to those from previous studies on
idiopathic PAP. 
The possibility of spontaneous resolution was initially pro-
posed in the Rosen et al. report (1). They described the pati-
ents as either having stable persistent symptoms, progressive
deterioration in their process, or spontaneous improvement.
Other authors also have made similar observations. Kariman
and colleagues (28) reported that spontaneous resolution oc-
curred in 24% of a series of 23 patients. Seymour and Presneill
(10) reported that 24 of 303 patients (7.9%) showed a signif-
icant degree of spontaneous improvement. The reason for the
variation in the amount of spontaneous resolution reported
by different studies and authors may be because authors used
different individual criteria. In our study, we defined spon-
taneous resolution as radiographic and symptomatic improve-
ment until follow-up. Based on these criteria, 5 of 38 pati-
ents (13%) showed spontaneous resolution. In the survival
analysis, there was no difference between the lavage and no
lavage groups (Fig. 3). The mean follow-up period from the
time of whole lung lavage of 3 yr was too short to compare
the survival between the lavage and no lavage groups. More-
over, one patient died soon after therapeutic lavage in the
lavage group and one patient died of stomach cancer in the
no lavage group, but neither death was directly related to
PAP. 
This study has several limitations; it was a retrospective
study, the follow-up period was too short to analyze survival
outcomes, and the smoking history of the patients was una-
vailable.
This is the first multicenter study to analyze 38 Korean
patients with idiopathic PAP. The clinical features and pul-
monary parameters of Korean patients with idiopathic PAP
are consistent with reports in other published studies. Whole
lung lavage appears to be the most effective form of treatment.
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